GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (FRA:ER4) » Definitions » EV-to-EBITDA

Emergent BioSolutions (FRA:ER4) EV-to-EBITDA : -3.70 (As of Nov. 13, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Emergent BioSolutions's enterprise value is €1,297.0 Mil. Emergent BioSolutions's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was €-350.5 Mil. Therefore, Emergent BioSolutions's EV-to-EBITDA for today is -3.70.

The historical rank and industry rank for Emergent BioSolutions's EV-to-EBITDA or its related term are showing as below:

FRA:ER4' s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.5   Med: 9.54   Max: 38.39
Current: -3.7

During the past 13 years, the highest EV-to-EBITDA of Emergent BioSolutions was 38.39. The lowest was -45.50. And the median was 9.54.

FRA:ER4's EV-to-EBITDA is ranked worse than
100% of 714 companies
in the Drug Manufacturers industry
Industry Median: 15.065 vs FRA:ER4: -3.70

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-11-13), Emergent BioSolutions's stock price is €10.20. Emergent BioSolutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-10.473. Therefore, Emergent BioSolutions's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Emergent BioSolutions EV-to-EBITDA Historical Data

The historical data trend for Emergent BioSolutions's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions EV-to-EBITDA Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.16 8.99 5.41 -35.28 -1.69

Emergent BioSolutions Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.56 -1.80 -1.69 -2.78 -3.08

Competitive Comparison of Emergent BioSolutions's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's EV-to-EBITDA falls into.



Emergent BioSolutions EV-to-EBITDA Calculation

Emergent BioSolutions's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1296.966/-350.474
=-3.70

Emergent BioSolutions's current Enterprise Value is €1,297.0 Mil.
Emergent BioSolutions's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-350.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emergent BioSolutions  (FRA:ER4) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Emergent BioSolutions's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.20/-10.473
=At Loss

Emergent BioSolutions's share price for today is €10.20.
Emergent BioSolutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.473.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Emergent BioSolutions EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions Business Description

Traded in Other Exchanges
Address
300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines